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Abstract
Background: Chromobacterium violaceum is a proteobacterium found in soil and water in tropical regions. The
organism rarely causes infection in humans, yet can cause a severe systemic infection by entering the bloodstream
via an open wound.
Case presentation: We recently identified a case of severe bacteremia caused by Chromobacterium violaceum at
the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam. Here, we describe how rapid microbiological
identification and a combination of antimicrobials was used to successfully treat this life threatening infection in a
four-year-old child.
Conclusions: This case shows the need for rapid diagnosis when there is the suspicion of a puncture wound
contaminated with water and soil in tropical regions. We suggest that the aggressive antimicrobial combination
used here is considered when this infection is suspected.
Background
Chromobacterium violaceum is a Gram-negative faculta-
tively anaerobic proteobacterium that can be isolated
from water and soil in tropical and sub-tropical regions
[1]. The organism rarely infects humans; yet, occasion-
ally, the organism can establish a severe systemic infec-
tion by entering the bloodstream via an open wound.
There has been a recent surge in interest in human
Chromobacterium violaceum infections in South East
Asia, potentially as a consequence of increased reporting
and awareness [2]. In 2008 we documented the first
ever case in Ho Chi Minh City [3]. Since this primary
case, three more infections have been observed in the
city hospitals. Due to the rapid progression of human
Chromobacterium violaceum infections, a systemic in-
fection with this bacterium is typically fatal and no effica-
cious treatment regimes have ever been described. Here
we report a case of Chromobacterium violaceum in Ho
Chi Minh City that was successfully treated with a com-
bination of antimicrobials.
Case presentation
A four-year-old HIV negative male presented at the
Hospital for Tropical Diseases in Ho Chi Minh City with
a puncture wound on his right ankle. He was admitted
and had a three-day history of fever, fatigue, vomiting and
anorexia. He had previously been diagnosed with pulmon-
ary Tuberculosis when three years old and had previously
been taking a combination of rifampicin, 4-aminosalicylic
acid and ethambutol for eight months. He had no other
underlying diseases. On admission he had a pulse rate
of 180 beats/minute, low blood pressure, a respiration
rate of 57 breaths/minute, crackling chest sounds and pale
sclera. The cervical lymph nodes were swollen, measuring
2 cm in diameter. He had displayed evidence of hepato-
megaly, but was not jaundiced and had two small blisters
on the abdomen.
The initial clinical diagnosis was acute sepsis. An anti-
microbial regime of 200 mg/day of amikacin, 150 mg/day
of vancomycin and 1.25 g/day of ceftriaxone was initiated
immediately. On admission, the hematology results showed
a normal white blood cell count with low hemoglobin
(Table 1). The blood chemistry was also unremarkable
(Table 2), apart from a C reactive protein concentration of
312 mg/l (normal range 0–5 mg/l), indicating severe sepsis.
Radiography showed new pulmonary infiltrations, yet this
was deemed not to be consistent with a progression of
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tuberculosis, a sputum smear was negative and fur-
ther smears from a stomach aspirate and bronchial
fluids were also negative. A blood sample was taken
and inoculated into a Peds Plus/F BACTEC bottle
and incubated at 37°C in an automated BACTEC
9240 machine (Becton Dickinson, United Kingdom).
After 24 hours a positive result was recorded, and a
Gram-negative bacilli was identified. Subcultures were
performed on blood agar and nutrient agar plates and
incubated aerobically at 35°C. After overnight incuba-
tion the agar plates demonstrated numerous small colonies
with a dark violet metallic pigmentation. This pigmenta-
tion is unique to Chromobacterium violaceum, differ-
entiating the organism from other tropical, soil dwelling
organisms, and is due to the production of a chemical
called violacein [4]. Identification of Chromobacterium
violaceum was confirmed by a positive mannitol test and
API 20NE [3]. The bacterial isolate was tested for
susceptibility to a range of antimicrobials (cefapine, cipro-
floxacin, amikacin, ofloxacin, imipenem, ceftriaxone, cefta-
zidime and piperacillin/tazobactam) on Mueller-Hinton
agar, and interpreted according to the CLSI guide-
lines for non-Enterobaceriaceae Gram-negatives [5].
The phenomenon of intrinsic antimicrobial resistance
in Chromobacterium violaceum is well described [6].
However, this isolate did not exhibit comprehensive
resistant to any of the tested antimicrobials. On day three
the antimicrobial therapy was changed to 330 mg/8 hours
of meropenem, 150 mg/8 hours of ciprofloxacin and 150
mg/6 hours of vancomycin. This antimicrobial regime was
continued for 23 days until the patient was afebrile and
had no symptoms synonymous with bacteremia, add-
itional blood cultures were not performed. The child
made a complete recovery without complications.
Conclusions
The first reported human infection with Chromobacterium
violaceum was in Malaysia in 1927, and less than 100 cases
have been described since [7-10]. This case in Ho Chi
Minh City shows the need for rapid diagnosis when there
is the suspicion of a puncture wound contaminated with
water and soil in tropical regions. A high C reactive
protein, despite having a low specificity, was used as
an indicator of severe sepsis. The subsequent early
blood culture for isolation, identification and anti-
microbial susceptibility were used to diagnose this in-
fection and are essential for initiating early antimicrobial
therapy. Although this type of infection is rare it should be
factored into the differential diagnosis with Burkholderia
spp., Aeromonas spp. and Pseudomonas spp. in tropical
and sub-tropical regions, as a substantial delay in treat-
ment can lead to rapid decline and death. We hope that
this communication will continue to raise the awareness
of this potentially fatal infection and we suggest that the
aggressive antimicrobial combination used here is consid-
ered when this infection is suspected.
Consent
Written informed consent was obtained from the
patient's parent for publication of this Case report and
any accompanying images. A copy of the written consent
is available for review by the Editor of this journal.
Table 1 Hematology results over Chromobacterium violaceum infection
Days a WBC (K/μL) % Neutrophils Haemoglobin (g/dL) Platelets (K/μl) C-reactive protein (mg/l)
1 8.96 77.8 11 154 312
2 9.26 83.4 14 61 298
3 8.36 84 12.8 40 241
5 4.14 57.8 11.6 50 107
6 7.85 55.6 11.4 81 93
10 14.7 62.7 9.6 392 67
12 12.85 76.9 7.4 590 51
17 14.93 69.5 11.9 635 48
18 12.37 56.7 12.2 527 16
Normal ranges, WBC; 4.3-10.8 K/μL, Neutrophils; 45 – 74%, Haemoglobin; 14 – 18 g/dL, Platelets; 150 – 350 K/μl, CRP; 0 – 5 mg/l.
a Days post admission.
Table 2 Blood chemistry results of a Chromobacterium
violaceum infection on admission
Chemical test (normal range) Result
Sodium (135–145 mmol/l) 130 mmol/l
Potassium (3.5-5.0 mmol/l) 3.15 mmol/l
Chlorine (98–106 mmol/l) 84.8 mmol/l
Calcium (2.15-2.6 mmol/l) 2.09 mmol/l
Creatinine (53–130 μmol/l) 103 μmol/l
SGPT (0–40 Ul/l) 22 UI/l
GGT (7–50 UI/l) 24 UI/l
Lactate IV (0.6-2.4 mmol/l) 5.28 mmol/l
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